A prospective observational cohort study of lenvatinib as initial treatment in patients with BCLC-defined stage B hepatocellular carcinoma

Abstract Background Transarterial chemoembolization (TACE) is the standard treatment for intermediate stage hepatocellular carcinoma (HCC) (Barcelona Clinic Liver Cancer [BCLC] B). However, it often leads to a poor prognosis and decreased hepatic function especially in patients with BCLC substage B2...

詳細記述

保存先:
書誌詳細
主要な著者: Satoshi Kobayashi, Taito Fukushima, Makoto Ueno, Satoshi Moriya, Makoto Chuma, Kazushi Numata, Kota Tsuruya, Shunji Hirose, Tatehiro Kagawa, Nobuhiro Hattori, Tsunamasa Watanabe, Kotaro Matsunaga, Michihiro Suzuki, Haruki Uojima, Hisashi Hidaka, Chika Kusano, Motoko Suzuki, Manabu Morimoto
フォーマット: Artigo
言語:Inglês
出版事項: BMC 2022-05-01
シリーズ:BMC Cancer
主題:
Hepatocellular carcinoma
Intermediate stage
Substage
Lenvatinib
TACE
オンライン･アクセス:https://doi.org/10.1186/s12885-022-09625-x
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料